Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%
Public ClinicalTrials.gov record NCT04986202. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomised, Double-blind, Placebo-controlled, Multi-center Sequential Phase 2b and Phase 3 Study to Evaluate the Efficacy and Safety of AZD4831 Administered for Up to 48 Weeks in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%
Study identification
- NCT ID
- NCT04986202
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 711 participants
Conditions and interventions
Interventions
- AZD4831 Drug
- Placebo Other
Drug · Other
Eligibility (public fields only)
- Age range
- 40 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 29, 2021
- Primary completion
- Mar 26, 2024
- Completion
- Mar 26, 2024
- Last update posted
- Aug 26, 2025
2021 – 2024
United States locations
- U.S. sites
- 21
- U.S. states
- 14
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Alexander City | Alabama | 35010 | — |
| Research Site | Little Rock | Arkansas | 72205 | — |
| Research Site | Sacramento | California | 95821 | — |
| Research Site | Miami | Florida | 33144 | — |
| Research Site | Miami Beach | Florida | 33140 | — |
| Research Site | Ocala | Florida | 34471 | — |
| Research Site | Evanston | Illinois | 60208 | — |
| Research Site | Hazel Crest | Illinois | 60429 | — |
| Research Site | Shreveport | Louisiana | 71105 | — |
| Research Site | Baltimore | Maryland | 21229 | — |
| Research Site | St Louis | Missouri | 63136 | — |
| Research Site | Buffalo | New York | 14215 | — |
| Research Site | New York | New York | 10019 | — |
| Research Site | Rosedale | New York | 11422 | — |
| Research Site | Chapel Hill | North Carolina | 27599 | — |
| Research Site | Pinehurst | North Carolina | 28374 | — |
| Research Site | Cleveland | Ohio | 44195 | — |
| Research Site | Philadelphia | Pennsylvania | 19107 | — |
| Research Site | Knoxville | Tennessee | 37916 | — |
| Research Site | Tullahoma | Tennessee | 37388 | — |
| Research Site | Norfolk | Virginia | 23510 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 150 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04986202, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 26, 2025 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04986202 live on ClinicalTrials.gov.